Adjunctive loxapine in a clozapine-resistant cohort of schizophrenic patients

Annals of Clinical Psychiatry

Volumn 8, Issue 4, 1996, Pages 193-197

  Mowerman, Samuel ^a,b   Siris, Samuel G ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

Clozapine; Loxapine; Schizophrenia; Treatment resistant; Typical neuroleptic

Indexed keywords

CLOZAPINE; LOXAPINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RATING SCALE; SCHIZOIDISM; SCHIZOPHRENIA; SYMPTOM;

EID: 0030477129     PISSN: 10401237     EISSN: None     Source Type: Journal    
DOI: 10.3109/10401239609147759     Document Type: Article

References (16)

1. Kane JM, Woerner MG, Pollack S, Safferman AZ, Lieberman JA: Does clozapine cause tardive dyskinesia? J Clin Psychiatry 1993; 54:327-330
2. Marder SR, Van Putten T: Who should receive clozapine? Arch Gen Psychiatry 1988; 45:865-867
3. Juul Povlsen U, Noring U, Fog R, Gerlach, J: Tolerability and therapeutic effect of clozapine: A retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr Scand 1985; 71:176-185
4. Kuha S, Miettinen E: Long term effect of clozapine in schizophrenia: A retrospective study of 108 chronic schizophrenics treated with clozapine for up to 7 years. Nord Psykiatr Tidsskr 1986; 40:225-230
5. Gerlach J, Jorgensen EO, Peacock L: Long term experience with clozapine in Denmark: Research and clinical practice. Psychopharmacology (Berl) 1989; 99:592-596
6. Reid WH, Pham VA, Rago W: Clozapine use by state programs: Public mental health systems respond to a new medication. Hosp Commun Psychiatry 1993; 44:739-743
7. Small JG, Milstein V, Marhenke JD, Hall DD, Kellams JJ: Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis. J Clin Psychiatry 1987; 48:263-267
8. Kane J, Honigfeld G, Singer J, Meltzer H, and the Clozaril Collaborative Study Group: Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796
9. Meltzer HY, Bastani B, Kwon K, Ramirez LF, Burnett S, Sharpe J: A prospective study of clozapine in treatment-resistant schizophrenic patients. Psychopharmacology (Berl) 1989; 99:S68-S72
10. Owen RR, Beake BJ, Marby D, Dessain EC, Cole JO: Response to clozapine in chronic psychotic patients. Psychopharmacol Bull 1989; 25:253-256
11. Naber D, Holzbach R, Perro C, Hippius H: Clinical management of clozapine patients in relation to efficacy and side effects. Br J Psychiatry 1992; 160 (suppl 17): 54-59
12. Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH: Clinical and biological response to clozapine in patients with schizophrenia: Crossover comparison with fluphenazine. Arch Gen Psychiatry 1992; 49:345-353
13. Woerner MG, Manuzza S, Kane JM: Anchoring the BPRS: An aid to improved reliability. Psychopharmacol Bull 1988; 24:112-117
14. Farde L, Wiesel FA, Nordstrom AL, Sedvall G: D1 and D2 dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology (Berl) 1989; 99 (Suppl):S28-S31
15. 2 receptor occupancy in patients treated with classical neuroleptics and clozapine: Relationship to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49:538-544
16. Lahti RA, Evans DL, Stratman NC, Figur LM: Dopamine D4 vs D2 receptor selectivity of dopamine receptor antagonists: Possible therapeutic implications. Eur J Pharmacol 1993; 236:483-486